My watch list  


News Fenofibrate

  • GENFIT: Promising GFT505 results in Phase II

    GENFIT announced positive results in Phase II with its most advanced drug candidate, GFT505, in prediabetic patients with atherogenic dyslipidemia and abdominal obesity (study GFT505-2083). Analysis of the results of this clinical trial showed that GFT505 was very well tolerated at the dose of 80m more

  • Abbott to Acquire Solvay Pharmaceuticals Business

    Abbott announced a definitive agreement with the Solvay Group for Abbott to acquire Solvay's pharmaceuticals business for EUR 4.5 billion(US$6.6 billion) in cash, providing Abbott with a large and complementary portfolio of pharmaceutical products and a significant presence in key global emerging ma more

  • LifeCycle Pharma Enters Three Distinct Strategic Collaboration Agreements With Global Pharmaceutical Companies

    LifeCycle Pharma A/S announced that it has entered into three strategic collaboration agreements with Sandoz Inc. (an affiliate of Novartis AG), Merck Generics (a subsidiary of Merck KGaA of Darmstadt, Germany) and H. Lundbeck A/S. Sandoz and LifeCycle Pharma have entered into an exclusive developm more

All news on fenofibrate

Publications Fenofibrate

All publications on fenofibrate


Fenofibrate Fenofibrate is a drug of the fibrate class. The development of Fenofibrate was discovered by Groupe Fournier SA , before it was acquired by Solvay Pharmaceutical in 2005. It is mainly used to reduce cholesterol levels in patients ... more


This is where you can add this topic to your personal favourites

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE